Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 69

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 69
---
 effect to any estimate of forfeitures related to service-based vesting but assumes that the director will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note M to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |

70

The table below shows the aggregate number of option awards outstanding for each of our non-employeedirectors as of December 31, 2024:

| Name               |     | Aggregate Option Awards Outstanding (#) |
| Thomas D. Anderson |     | 98,000 (1)                              |
| John B. Bode       |     | 98,000 (2)                              |
| Douglas W. Calder  |     | 98,000 (2)                              |
| Wendy Dixon, Ph.D. |     | 98,000 (3)                              |
| Tamara A. Favorito |     | 135,900 (4)                             |
| Alvin Shih, M.D.   |     | 98,000 (5)                              |
| Corey Watton       |     | 98,000 (2)                              |

| (1) | As of December 31, 2024, 19,600 shares underlying these options were vested. Of the remaining shares underlying these options, (a) 39,200 will vest in two equal annual installments beginning on August 7, 2025, and (b) 39,200 shares underlying these options will vest on the earlier of (i) May 13, 2025, or (ii) one day prior to the Annual Meeting, subject to continued service. |

| (2) | As of December 31, 2024, 19,600 shares underlying these options were vested. Of the remaining shares underlying these options, (a) 39,200 will vest in two equal annual installments beginning on May 3, 2025, and (b) 39,200 shares underlying these options will vest on the earlier of (i) May 13, 2025, or (ii) one day prior to the Annual Meeting, subject to continued service. |

| (3) | As of December 31, 2024, 19,600 shares underlying these options were vested. Of the remaining shares underlying these options, (a) 15,000 will vest in two equal annual installments